



KinDex Pharmaceuticals Launches with \$5 Million Series A Funding Led by Polaris Partners

***Company Will Initiate Phase 2 Drug Trial for Type 2 Diabetics
and Undertake Additional Studies in Obesity and Brown Fat Biology***

March 25, 2014, Seattle, WA, -- KinDex Pharmaceuticals (www.kindexpharmaceuticals.com), a biotechnology company focused on discovering and developing molecules that modulate key regulatory networks associated with obesity, inflammation and chronic disease, announced today an initial \$5 million Series A funding, which includes leading venture capital firm Polaris Partners. KinDex Pharmaceuticals was formed by the reorganization of KinDex Therapeutics, LLC, in parallel with the investment.

"We are very excited about the opportunity to work strategically with Polaris," said Jeffrey Bland, Ph.D., CEO of KinDex Pharmaceuticals. "Their investment will help us initiate the planned Phase 2 trial of our most advanced candidate, KDT501, in Type 2 diabetic patients as well as undertake additional preclinical and mechanistic studies in brown fat biology. Polaris is known to build strong relationships with their companies and we look forward to accessing their expertise and extended network as we continue to establish value in our portfolio."

KinDex is actively developing pleiotropic small molecules derived from hops that regulate the 'cross-talk' between macrophages and adipocytes and influence the cell inflammasome. Published mechanistic and animal studies on KDT 501 indicate that it influences brown fat cell differentiation, which is important in thermogenesis and obesity management. In addition, animal studies demonstrate that the KinDex Pharmaceuticals candidate compounds have the potential to not only improve glucose homeostasis, but also modify total cholesterol and triglycerides and reduce body weight gain, while exhibiting the ability to reduce the systemic inflammatory effects resulting from postprandial metabolic endotoxemia.

About KinDex Pharmaceuticals

KinDex's molecules have demonstrated efficacy in *in vitro* and *in vivo* models of diabetes and inflammation. The company has successfully completed Phase 1 clinical safety studies of their most advanced drug candidate, KDT501, and anticipates initiating proof-of-concept efficacy studies in diabetic patients. The privately held biotech's scientific advisory board includes biotechnology luminaries Dr. Paul Schimmel of The Scripps Research Institute, Dr. John Kozarich of ActivX and Dr. Benjamin Cravatt of The Scripps Research Institute. Read about KinDex's research in their most recent PlosOne publication:

<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0087848;jsessionid=D00E83DAA6EAE0CB0F37ADF52AE8A033>

Contact: Annette Giarde, KinDex Pharmaceuticals Operations Manager 206-922-2912
annettegiarde@kindexpharmaceuticals.com